Harnessing MerTK agonism for targeted therapeutics

Phagocytosis plays important roles both in homeostasis and under pathological conditions. Fcγ receptor-mediated phagocytosis has been exploited as an integral mechanism for antibody-based therapies. Unlike Fcγ receptor-mediated phagocytosis, MerTK-mediated phagocytic clearance is immunologically sil...

Descripción completa

Detalles Bibliográficos
Autores principales: Kedage, Vivekananda, Ellerman, Diego, Chen, Yongmei, Liang, Wei-Ching, Borneo, Joven, Wu, Yan, Yan, Minhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927767/
https://www.ncbi.nlm.nih.gov/pubmed/31852344
http://dx.doi.org/10.1080/19420862.2019.1685832
Descripción
Sumario:Phagocytosis plays important roles both in homeostasis and under pathological conditions. Fcγ receptor-mediated phagocytosis has been exploited as an integral mechanism for antibody-based therapies. Unlike Fcγ receptor-mediated phagocytosis, MerTK-mediated phagocytic clearance is immunologically silent. Here, we describe a bispecific antibody approach to harness MerTK for targeted clearance without inducing proinflammatory cytokine release associated with Fcγ receptor engagement. We generated bispecific antibodies targeting live B cells or amyloid beta aggregates to demonstrate the feasibility and versatility of this new approach.

Ejemplares similares